drugset / Trial / NCT07010744
Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
The Goal of this this clinical trial is to assess and compare the eradication rate of triple and quadruple therapy during treating helicobacter pylori infection among patients presented with dyspepsia. It will also assess the patient reported adverse events among two groups. H pylori infection will be confirmed by CLO (RUT) test and stool antigen test both. Standard triple therapy will be based on Esomeprazole 20 mg BD, Clarithromycin 500mg BD and Amoxicillin 1gm BD. Bismuth Quadruple therapy consists of Bismuth subcitrate 120mg QDS, Tetracycline 500mg QDS and Metronidazole 500mg TDS. Patient will be confirmed H pylori eradication 4 weeks after completion of treatment by Stool antigen test only.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Metronidazole | Small molecule | 500 mg | — |
| Subject | Tetracycline | Unknown | 500 mg | — |
| Subject | bismuth subcitrate | Unknown | 120 mg | — |
| Background | Esomeprazole | Small molecule | 20 mg | — |
| Background | Quadruple therapy | Unknown | 20 mg | — |